Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Stock Short Interest Rises 134.8%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 580 shares, a growth of 134.8% from the September 30th total of 247 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 1,840 shares, the short-interest ratio is presently 0.3 days.

Molecular Partners Trading Up 2.9%

Shares of Molecular Partners stock traded up $0.10 during trading hours on Friday, reaching $3.63. 1,523 shares of the company’s stock were exchanged, compared to its average volume of 4,315. The firm has a market capitalization of $146.74 million, a price-to-earnings ratio of -2.13 and a beta of 1.11. Molecular Partners has a 52-week low of $3.51 and a 52-week high of $5.36. The company has a fifty day moving average of $4.05 and a 200-day moving average of $4.18.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.08. On average, equities research analysts anticipate that Molecular Partners will post -1.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.